Benzinga | Apr 29, 2021 07:21AM EDT

Blueprint Medicines Q1 EPS $(1.72) Beats $(1.86) Estimate, Sales $21.58M Beat $17.25M Estimate

Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.72) per share which beat the analyst consensus estimate of $(1.86) by 7.53 percent. This is a 18.48 percent increase over losses of $(2.11) per share from the same period last year. The company reported quarterly sales of $21.58 million which beat the analyst consensus estimate of $17.25 million by 25.08 percent. This is a 249.86 percent increase over sales of $6.17 million the same period last year.